Production (Stage)
Ernexa Therapeutics Inc.
ERNA
$2.29
-$0.08-3.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -46.09M | -44.54M | -44.93M | -23.92M | -22.90M |
| Total Depreciation and Amortization | 1.17M | 1.64M | 2.05M | 2.12M | 1.60M |
| Total Amortization of Deferred Charges | 4.81M | 5.26M | 2.40M | 1.22M | 748.00K |
| Total Other Non-Cash Items | 28.69M | 23.78M | 23.61M | 1.96M | 2.10M |
| Change in Net Operating Assets | -2.73M | -1.98M | -81.00K | 2.13M | 343.00K |
| Cash from Operations | -14.15M | -15.84M | -16.95M | -16.49M | -18.11M |
| Capital Expenditure | -268.00K | -369.00K | -388.00K | -369.00K | -120.00K |
| Sale of Property, Plant, and Equipment | 0.00 | 4.00K | 4.00K | 4.00K | 4.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -268.00K | -365.00K | -384.00K | -365.00K | -116.00K |
| Total Debt Issued | 6.14M | 5.29M | 14.58M | 19.41M | 19.41M |
| Total Debt Repaid | -- | -- | -1.50M | -1.50M | -1.50M |
| Issuance of Common Stock | 1.14M | 1.14M | 0.00 | 0.00 | 320.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -8.00K | -8.00K | -16.00K | -16.00K | -16.00K |
| Other Financing Activities | -149.00K | -169.00K | -110.00K | -285.00K | -271.00K |
| Cash from Financing | 7.13M | 6.26M | 12.95M | 17.61M | 17.94M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.29M | -9.94M | -4.38M | 749.00K | -281.00K |